Get the Rxrx Stock Quote and Insights on Recursion Pharmaceuticals

Recursion Pharmaceuticals, the parent company of rxrx, is a biotechnology company focused on developing novel therapeutics for patients with serious diseases.

The company's innovative approach to drug discovery has led to the development of several promising candidates.

Recursion Pharmaceuticals has a strong track record of innovation, with a pipeline of over 20 programs in various stages of development.

Their unique approach to drug discovery involves using artificial intelligence and machine learning to identify potential therapeutic targets and optimize drug candidates.

Recursion Pharmaceuticals, the company behind the rxrx stock quote, has seen a significant increase in revenue over the past year, jumping to $44.58 million in 2023, a 11.88% boost from the previous year's $39.84 million.

However, despite this growth, the company still reported a substantial loss of -$328.07 million in 2023, which is a 37.0% increase from the previous year's losses.

Here's a snapshot of Recursion Pharmaceuticals' financial health:

The Altman Z-Score, a measure of a company's likelihood of bankruptcy, indicates that Recursion Pharmaceuticals is in a safe position, while the Beneish M-Score, which detects accounting manipulation, suggests that the company is not engaging in any suspicious activities.

Recursion Pharmaceuticals saw a revenue increase of 11.88% in 2023, reaching $44.58 million.

Their revenue grew from $39.84 million in 2022, a notable improvement. However, losses were substantial, standing at -$328.07 million.

Losses in 2023 were 37.0% more than the previous year's -$238.05 million.

It's worth noting that the company's financial performance has room for improvement, but the revenue growth is a positive sign.

Here's a quick summary of Recursion Pharmaceuticals' revenue growth and losses over the past two years:

As a shareholder, it's essential to understand the performance of your investment. In the case of Recursion Pharmaceuticals, the company's shareholder returns have been a mixed bag. In the past 7 days, the company's shares returned 8.0%, outperforming the US Biotechs industry which returned 4.2%.

However, over the past year, Recursion Pharmaceuticals' shares have underperformed the US Biotechs industry, returning -24.5% compared to the industry's -4.3%. This is a notable difference, and one that investors should take into account when evaluating their investment.

Here's a breakdown of Recursion Pharmaceuticals' shareholder returns compared to other indices:

As you can see, Recursion Pharmaceuticals' shares have underperformed the US Market over the past year, returning -24.5% compared to the market's 22.7%. This is a significant difference, and one that investors should consider when evaluating their investment.

Explore further: Share Prices of Itc

Recursion Pharmaceuticals's revenue increased by 11.88% in 2023, reaching $44.58 million.

The company's losses were -$328.07 million, a 37.0% increase from the previous year.

Recursion Pharmaceuticals's share price has been volatile over the past 3 months compared to the US market. The current share price is $7.43, with a 52 week high of $15.74 and a 52 week low of $5.60.

Here's a breakdown of the share price changes over the past year:

Recursion Pharmaceuticals has a notable revenue growth rate of 91.6% over the past three years.

This is a significant increase, indicating the company's ability to expand its revenue streams. The 3-Year EBITDA Growth Rate, however, is a different story, with a decline of 26.8% over the same period.

The company's earnings per share (EPS) without non-recurring items have also seen a decline of 27.6% over the past three years. This suggests that the company may be experiencing some challenges in its profitability.

A look at the company's free cash flow (FCF) growth rate reveals an even more concerning trend, with a decline of 46% over the past three years. This could indicate that the company is struggling to generate cash from its operations.

Despite these challenges, analysts are still optimistic about the company's future prospects, with a 3-5 year total revenue growth rate estimate of 40.23%.

Recursion Pharmaceuticals, or RXRX, operates as a clinical-stage biotechnology company. They're working on decoding biology by combining technological innovations across various fields to industrialize drug discovery.

Their financial performance is a mixed bag, with revenue increasing by 11.88% in 2023 to $44.58 million, but losses ballooning to -$328.07 million, a 37% increase from the previous year.

The company's share price has been volatile, with a 14.2% average weekly movement, which is higher than the market average of 6.5%. This volatility is consistent with the biotechs industry average of 11.4%.

RXRX's share price has been stable over the past year, but is still higher than 75% of US stocks. The current share price is $7.43, a significant drop from the 52-week high of $15.74.

Here's a breakdown of RXRX's fundamental analysis scorecard: